Company intelligence / Profile preview

Albagen

United States

Ownership: Private
Development stage: Other

Overview

Albagen is a highly purified, hypoallergenic recombinant human serum albumin, formulated for stability and long-term storage with high monomer content. It is animal-free, with improved safety and purity characteristics compared to plasma-derived and some other recombinant forms. No clinical trial results are disclosed as this is a reagent/excipient-grade product, not an investigational or approved biologic drug.

Therapeutic areas: HematologyOther
Modalities: Recombinant protein
Industry: Non-Drug Biotech

Beyond the preview

Go deeper on Albagen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Albagen.

Explore the full profile